United States Osteoarthritis Therapeutics Market Report and Forecast 2025-2034
Description
The United States osteoarthritis therapeutics market was valued at USD 3.20 Billion in 2024, driven by an increasing aging population and growing prevalence of osteoarthritis across the region. The market is anticipated to grow at a CAGR of 7.10% during the forecast period of 2025-2034, with the values likely to reach USD 6.35 Billion by 2034. The market is driven by advancements in biologics, the increasing use of non-pharmacological treatments, and the growing focus on personalized therapies, which is expected to fuel market growth during the forecast period.
United States Osteoarthritis Therapeutics Market Overview
Osteoarthritis therapeutics include a range of treatments such as analgesics, nonsteroidal anti-inflammatory drugs, corticosteroid injections, physical therapy, and surgical options. These aim to relieve joint pain, reduce inflammation, enhance mobility, and slow the progression of cartilage degradation. The market was valued at USD 3.20 Billion in 2024 and is expanding due to an aging population, increasing obesity, and growing awareness of early treatment. Continued advancements in drug development and patient care are expected to drive sustained growth.
United States Osteoarthritis Therapeutics Market Growth Drivers
Increasing Prevalence of Osteoarthritis to Accelerate the Market Growth
The substantial and rising prevalence of osteoarthritis (OA) in the United States continues to be a major driver of growth in the osteoarthritis therapeutics market. According to Michael Langworthy et al., 2024, osteoarthritis affects approximately 9,961 individuals per 100,000 in the United States, with the overall lifetime risk of developing symptomatic osteoarthritis ranging between 41% and 45%. This high and increasing disease burden is fostering sustained demand for advanced therapeutic options, thereby accelerating market expansion.
United States Osteoarthritis Therapeutics Market Trends
Some of the notable trends in the market are surge in FDA approvals and a growing focus on government initiatives:
Rising FDA Approvals to Accelerate the Growth in the Market
The market is witnessing robust growth, largely driven by an increasing number of FDA approvals for novel treatments. A landmark development occurred in May 2023, when Grünenthal’s resiniferatoxin (RTX) received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for pain associated with knee osteoarthritis. This designation highlights the promising potential of RTX as a non-opioid therapy and is expected to expedite its development, offering hope for effective pain relief and advancing the market further.
Rising Initiatives to Make Novel Treatments Accessible to Patients to Drive United States Osteoarthritis Therapeutics Market Growth
The government is actively involved in bring the latest treatment alternatives to the patients. For instance, the government launched the NITRO program under ARPA-H in May 2023. The project was aimed at driving groundbreaking innovation in osteoarthritis (OA) treatment. The program focused on developing regenerative therapies to repair damaged joints, potentially reducing the need for invasive surgeries like joint replacements. Such initiatives are expected to significantly enhance market growth and offer a more effective solution for managing osteoarthritis, improving patients' quality of life, and addressing the healthcare burden associated with the condition.
United States Osteoarthritis Therapeutics Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
NSAIDs Segment Based on Drug Class to Witness Substantial Growth
Based on drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), other analgesics, corticosteroids, hyaluronic acid injections, and others. The NSAIDs segment is projected to dominate the market, attributed to the well-established efficacy of NSAIDs in reducing inflammation and relieving joint pain, and their widespread availability in both prescription and over-the-counter forms. Additionally, their relatively low cost and strong physician preference further contribute to their dominant market share.
Leading Players in the United States Osteoarthritis Therapeutics Market
The key features of the market report comprise clinical trials analysis, patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Bayer AG
Bayer AG, established in 1863 and headquartered in Leverkusen, Germany, is a leading company in the market. Its product, Aleve (Naproxen Sodium), is a well-known pain reliever used in the treatment of osteoarthritis. Bayer has been involved in clinical studies, including trials for assessing treatment responsiveness to medications like naproxen for osteoarthritis stiffness. These initiatives highlight Bayer’s commitment to advancing osteoarthritis care and pain management solutions for patients in the United States.
Pfizer Inc.
Headquartered in New York City and established in 1849, Pfizer is a leading pharmaceutical company with a notable presence in the United States market. Pfizer has been involved in the clinical development of tanezumab, an investigational non-opioid monoclonal antibody targeting nerve growth factor (NGF). The Phase 3 trial results published in 2018 demonstrated significant improvements in pain relief and physical function for osteoarthritis patients, highlighting Pfizer’s commitment to addressing unmet needs in OA treatment through innovative biologic therapies.
Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical leader actively involved in advancing osteoarthritis treatment in the United States. The company is committed to addressing chronic musculoskeletal conditions through innovative research and non-opioid therapeutic development. The company is actively developing LY3526318, a novel non-opioid drug targeting chronic osteoarthritis knee pain. Through continued innovation and focused therapeutic research, Lilly reinforces its strong commitment to addressing the growing burden of osteoarthritis.
Pacira Biosciences Inc.
Headquartered in Tampa, Florida, and established in 2007, Pacira BioSciences Inc. is a prominent American biopharmaceutical company specializing in non-opioid pain management. In March 2024, Pacira’s gene therapy candidate PCRX-201 received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for osteoarthritis of the knee, the first gene therapy to do so in this indication. Supported by positive Phase 1 data, PCRX-201 shows potential as a disease-modifying treatment. Alongside this innovation, Pacira continues to market Zilretta, an extended-release corticosteroid for osteoarthritis knee pain, reinforcing its leadership in the market.
Other key players in the market include Sanofi S.A., Bristol Myers Squibb, Assertio Holdings Inc., Anika Therapeutics Inc., and Bioventus LLC.
Key Questions Answered in the United States Osteoarthritis Therapeutics Market Report
United States Osteoarthritis Therapeutics Market Overview
Osteoarthritis therapeutics include a range of treatments such as analgesics, nonsteroidal anti-inflammatory drugs, corticosteroid injections, physical therapy, and surgical options. These aim to relieve joint pain, reduce inflammation, enhance mobility, and slow the progression of cartilage degradation. The market was valued at USD 3.20 Billion in 2024 and is expanding due to an aging population, increasing obesity, and growing awareness of early treatment. Continued advancements in drug development and patient care are expected to drive sustained growth.
United States Osteoarthritis Therapeutics Market Growth Drivers
Increasing Prevalence of Osteoarthritis to Accelerate the Market Growth
The substantial and rising prevalence of osteoarthritis (OA) in the United States continues to be a major driver of growth in the osteoarthritis therapeutics market. According to Michael Langworthy et al., 2024, osteoarthritis affects approximately 9,961 individuals per 100,000 in the United States, with the overall lifetime risk of developing symptomatic osteoarthritis ranging between 41% and 45%. This high and increasing disease burden is fostering sustained demand for advanced therapeutic options, thereby accelerating market expansion.
United States Osteoarthritis Therapeutics Market Trends
Some of the notable trends in the market are surge in FDA approvals and a growing focus on government initiatives:
Rising FDA Approvals to Accelerate the Growth in the Market
The market is witnessing robust growth, largely driven by an increasing number of FDA approvals for novel treatments. A landmark development occurred in May 2023, when Grünenthal’s resiniferatoxin (RTX) received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for pain associated with knee osteoarthritis. This designation highlights the promising potential of RTX as a non-opioid therapy and is expected to expedite its development, offering hope for effective pain relief and advancing the market further.
Rising Initiatives to Make Novel Treatments Accessible to Patients to Drive United States Osteoarthritis Therapeutics Market Growth
The government is actively involved in bring the latest treatment alternatives to the patients. For instance, the government launched the NITRO program under ARPA-H in May 2023. The project was aimed at driving groundbreaking innovation in osteoarthritis (OA) treatment. The program focused on developing regenerative therapies to repair damaged joints, potentially reducing the need for invasive surgeries like joint replacements. Such initiatives are expected to significantly enhance market growth and offer a more effective solution for managing osteoarthritis, improving patients' quality of life, and addressing the healthcare burden associated with the condition.
United States Osteoarthritis Therapeutics Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Hip Osteoarthritis
- Spinal Osteoarthritis
- Knee Osteoarthritis
- Hand Osteoarthritis
- Others
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Other Analgesics
- Corticosteroids
- Hyaluronic Acid Injections
- Others
- Tablets and Capsules
- Injections
- Creams and Gels
- Others
- Oral
- Parenteral
- Topical
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
NSAIDs Segment Based on Drug Class to Witness Substantial Growth
Based on drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), other analgesics, corticosteroids, hyaluronic acid injections, and others. The NSAIDs segment is projected to dominate the market, attributed to the well-established efficacy of NSAIDs in reducing inflammation and relieving joint pain, and their widespread availability in both prescription and over-the-counter forms. Additionally, their relatively low cost and strong physician preference further contribute to their dominant market share.
Leading Players in the United States Osteoarthritis Therapeutics Market
The key features of the market report comprise clinical trials analysis, patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Bayer AG
Bayer AG, established in 1863 and headquartered in Leverkusen, Germany, is a leading company in the market. Its product, Aleve (Naproxen Sodium), is a well-known pain reliever used in the treatment of osteoarthritis. Bayer has been involved in clinical studies, including trials for assessing treatment responsiveness to medications like naproxen for osteoarthritis stiffness. These initiatives highlight Bayer’s commitment to advancing osteoarthritis care and pain management solutions for patients in the United States.
Pfizer Inc.
Headquartered in New York City and established in 1849, Pfizer is a leading pharmaceutical company with a notable presence in the United States market. Pfizer has been involved in the clinical development of tanezumab, an investigational non-opioid monoclonal antibody targeting nerve growth factor (NGF). The Phase 3 trial results published in 2018 demonstrated significant improvements in pain relief and physical function for osteoarthritis patients, highlighting Pfizer’s commitment to addressing unmet needs in OA treatment through innovative biologic therapies.
Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical leader actively involved in advancing osteoarthritis treatment in the United States. The company is committed to addressing chronic musculoskeletal conditions through innovative research and non-opioid therapeutic development. The company is actively developing LY3526318, a novel non-opioid drug targeting chronic osteoarthritis knee pain. Through continued innovation and focused therapeutic research, Lilly reinforces its strong commitment to addressing the growing burden of osteoarthritis.
Pacira Biosciences Inc.
Headquartered in Tampa, Florida, and established in 2007, Pacira BioSciences Inc. is a prominent American biopharmaceutical company specializing in non-opioid pain management. In March 2024, Pacira’s gene therapy candidate PCRX-201 received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for osteoarthritis of the knee, the first gene therapy to do so in this indication. Supported by positive Phase 1 data, PCRX-201 shows potential as a disease-modifying treatment. Alongside this innovation, Pacira continues to market Zilretta, an extended-release corticosteroid for osteoarthritis knee pain, reinforcing its leadership in the market.
Other key players in the market include Sanofi S.A., Bristol Myers Squibb, Assertio Holdings Inc., Anika Therapeutics Inc., and Bioventus LLC.
Key Questions Answered in the United States Osteoarthritis Therapeutics Market Report
- What was the United States osteoarthritis therapeutics market value in 2024?
- What is the United States osteoarthritis therapeutics market forecast outlook for 2025-2034?
- What are the major factors aiding the United States osteoarthritis therapeutics market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major United States osteoarthritis therapeutics market trends?
- Which type is expected to dominate the market segment?
- Which drug class is projected to lead the market segment?
- Which dosage form is projected to lead the market segment?
- Which route of administration is anticipated to drive the market segment?
- Which end user is anticipated to drive the market segment?
- Which distribution channel is likely to dominate the market segment?
- Who are the key players involved in the United States osteoarthritis therapeutics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Osteoarthritis Therapeutics Market Overview
- 3.1 North America Osteoarthritis Therapeutics Market
- 3.1.1 North America Osteoarthritis Therapeutics Market Historical Value (2018-2024)
- 3.1.2 North America Osteoarthritis Therapeutics Market Forecast Value (2025-2034)
- 3.2 United States Osteoarthritis Therapeutics Market
- 3.2.1 United States Osteoarthritis Therapeutics Market Historical Value (2018-2024)
- 3.2.2 United States Osteoarthritis Therapeutics Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Osteoarthritis Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Osteoarthritis Epidemiology Scenario and Forecast
- 7.1 Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence of Osteoarthritis in United States
- 7.3 Total Diagnosed Cases of Osteoarthritis in United States
- 7.4 Gender-specific Prevalence of Osteoarthritis in United States
- 7.5 Age-specific Prevalence of Osteoarthritis in United States
- 7.6 Treatment Seeking Rate of Osteoarthritis in United States
- 8 United States Osteoarthritis Therapeutics Market Landscape
- 8.1 United States Osteoarthritis Therapeutics Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 United States Osteoarthritis Therapeutics Market: Product Landscape
- 8.2.1 Analysis By Type
- 8.2.2 Analysis By Drug Class
- 8.2.3 Analysis By Dosage Form
- 8.2.4 Analysis By Route of Administration
- 9 Clinical Trials and Pipeline Analysis
- 9.1 Analysis by Trial Registration Year
- 9.2 Analysis by Trial Status
- 9.3 Analysis by Trial Phase
- 9.4 Analysis by Therapeutic Area
- 9.5 Analysis by Geography
- 9.6 Drug Pipeline Assessment
- 10 Osteoarthritis Therapeutics Market Challenges and Unmet Needs
- 10.1 Treatment Pathway Challenges
- 10.2 Compliance and Drop-Out Analysis
- 10.3 Awareness and Prevention Gaps
- 11 Cost of Treatment
- 12 Osteoarthritis Therapeutics Market Dynamics
- 12.1 Market Drivers and Constraints
- 12.2 SWOT Analysis
- 12.2.1 Strengths
- 12.2.2 Weaknesses
- 12.2.3 Opportunities
- 12.2.4 Threats
- 12.3 PESTEL Analysis
- 12.3.1 Political
- 12.3.2 Economic
- 12.3.3 Social
- 12.3.4 Technological
- 12.3.5 Legal
- 12.3.6 Environment
- 12.4 Porter’s Five Forces Model
- 12.4.1 Bargaining Power of Suppliers
- 12.4.2 Bargaining Power of Buyers
- 12.4.3 Threat of New Entrants
- 12.4.4 Threat of Substitutes
- 12.4.5 Degree of Rivalry
- 12.5 Key Demand Indicators
- 12.6 Key Price Indicators
- 12.7 Industry Events, Initiatives, and Trends
- 12.8 Value Chain Analysis
- 13 United States Osteoarthritis Therapeutics Market Segmentation (218-2034)
- 13.1 United States Osteoarthritis Therapeutics Market (2018-2034) by Type
- 13.1.1 Market Overview
- 13.1.2 Hip Osteoarthritis
- 13.1.3 Spinal Osteoarthritis
- 13.1.4 Knee Osteoarthritis
- 13.1.5 Hand Osteoarthritis
- 13.1.6 Others
- 13.2 United States Osteoarthritis Therapeutics Market (2018-2034) by Drug Class
- 13.2.1 Market Overview
- 13.2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 13.2.3 Other Analgesics
- 13.2.4 Corticosteroids
- 13.2.5 Hyaluronic Acid Injections
- 13.2.6 Others
- 13.3 United States Osteoarthritis Therapeutics Market (2018-2034) by Dosage Form
- 13.3.1 Market Overview
- 13.3.2 Tablets and Capsules
- 13.3.3 Injections
- 13.3.4 Creams and Gels
- 13.3.5 Others
- 13.4 United States Osteoarthritis Therapeutics Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Topical
- 13.5 United States Osteoarthritis Therapeutics Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Specialty Clinics
- 13.5.4 Homecare Settings
- 13.5.5 Others
- 13.6 United States Osteoarthritis Therapeutics Market (2018-2034) by Distribution Channel
- 13.6.1 Market Overview
- 13.6.2 Hospital Pharmacies
- 13.6.3 Retail Pharmacies
- 13.6.4 Online Pharmacies
- 13.6.5 Others
- 14 Regulatory Framework
- 15 Patent Analysis
- 15.1 Analysis by Technology
- 15.2 Analysis by Publication Year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Codes
- 15.6 Analysis by Patent Valuation
- 16 Grants Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
- 17.1 Analysis by Funding Instances
- 17.2 Analysis by Type of Funding
- 17.3 Analysis by Funding Amount
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Leading Investors
- 17.6 Analysis by Geography
- 18 Strategic Initiatives
- 18.1 Analysis by Partnership Instances
- 18.2 Analysis by Type of Initiatives
- 18.3 Analysis by Leading Players
- 18.4 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis
- 19.2 Sanofi S.A.
- 19.2.1 Financial Analysis
- 19.2.2 Product Portfolio
- 19.2.3 Demographic Reach and Achievements
- 19.2.4 Company News and Developments
- 19.2.5 Certifications
- 19.3 Bayer AG
- 19.3.1 Financial Analysis
- 19.3.2 Product Portfolio
- 19.3.3 Demographic Reach and Achievements
- 19.3.4 Company News and Developments
- 19.3.5 Certifications
- 19.4 Pfizer Inc.
- 19.4.1 Financial Analysis
- 19.4.2 Product Portfolio
- 19.4.3 Demographic Reach and Achievements
- 19.4.4 Company News and Developments
- 19.4.5 Certifications
- 19.5 Eli Lilly and Company
- 19.5.1 Financial Analysis
- 19.5.2 Product Portfolio
- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Company News and Developments
- 19.5.5 Certifications
- 19.6 Bristol Myers Squibb Company
- 19.6.1 Financial Analysis
- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Company News and Developments
- 19.6.5 Certifications
- 19.7 Assertio Holdings Inc.
- 19.7.1 Financial Analysis
- 19.7.2 Product Portfolio
- 19.7.3 Demographic Reach and Achievements
- 19.7.4 Company News and Developments
- 19.7.5 Certifications
- 19.8 Pacira Biosciences Inc.
- 19.8.1 Financial Analysis
- 19.8.2 Product Portfolio
- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Company News and Developments
- 19.8.5 Certifications
- 19.9 Bioventus LLC
- 19.9.1 Financial Analysis
- 19.9.2 Product Portfolio
- 19.9.3 Demographic Reach and Achievements
- 19.9.4 Company News and Developments
- 19.9.5 Certifications
- 20 Osteoarthritis Therapeutics Market - Distribution Model (Additional Insight)
- 20.1 Overview
- 20.2 Potential Distributors
- 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 22 Payment Methods (Additional Insight)
- 22.1 Government Funded
- 22.2 Private Insurance
- 22.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
